Abstract:Due to the success story of biomarker-driven targeted therapy, most NSCLC guidelines agree that molecular reflex testing should be performed in all cases with non-squamous cell carcinoma (non-SCC). In contrast, testing recommendations for squamous cell carcinoma (SCC) vary considerably, specifically concerning the exclusion of patients of certain age or smoking status from molecular testing strategies. We performed a retrospective single-center study examining the value of molecular reflex testing in an unselected cohort of 316 consecutive lung SCC cases, tested by DNA- and RNA-based next-generation sequencing (NGS) at our academic institution between 2019 and 2023. Clinicopathological data from these cases were obtained from electronic medical records and correlated with sequencing results. In 21/316 (6.6%) cases, we detected an already established molecular target for an approved drug. Among these were seven cases with an EGFR mutation, seven with a KRAS G12C mutation, four with an ALK fusion, two with an EGFR fusion and one with a METex14 skipping event. All patients harboring a targetable alteration were >50 years of age and most of them had >15 pack-years, questioning restrictive molecular testing strategies. Based on our real-world data, we propose a reflex testing workflow using DNA- and RNA-based NGS that includes all newly diagnosed NSCLC cases, irrespective of histology, but also irrespective of age or smoking status.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is related to the molecular detection strategy for squamous cell carcinoma (SCC) in non - small - cell lung cancer (NSCLC). Specifically, the authors aim to provide evidence that, compared with adenocarcinoma (AC), although the frequency of treatable targets in SCC is lower, there are still a significant number of treatable targets. In addition, the study also explores whether most SCC patients with these treatable targets meet the criteria recommended for molecular detection in current guidelines, that is, being younger than 50 years old or having a smoking history of less than 15 pack - years. Through this study, the authors hope to propose a more extensive molecular detection strategy, that is, to perform molecular detection on all newly diagnosed NSCLC cases, regardless of their histological type, age or smoking status. ### Summary of main problems: 1. **Treatable targets in SCC**: Verify whether there are treatable molecular targets in SCC and the frequency of these targets. 2. **Molecular detection criteria**: Evaluate whether the molecular detection criteria (such as age and smoking history) recommended in current guidelines are applicable to SCC patients. 3. **Necessity of extensive molecular detection**: Based on actual data, propose a recommendation for extensive molecular detection of all newly diagnosed NSCLC cases. ### Research background: - Targeted therapies have revolutionized the treatment of NSCLC, especially adenocarcinoma (AC), because there is a high proportion of treatable gene mutations in AC. - Current guidelines generally recommend extensive molecular detection for all newly diagnosed AC cases, but there is a great deal of controversy regarding the detection recommendation for SCC. - Some guidelines recommend molecular detection for SCC only in specific situations (such as young patients or light smokers), while other guidelines recommend detection for all SCC cases. ### Research methods: - A retrospective single - center study, analyzing 316 consecutive diagnosed lung SCC cases between 2019 and 2023. - Molecular detection was performed using DNA - and RNA - based next - generation sequencing (NGS) techniques. - Clinical pathological data were collected and correlated with sequencing results. ### Main findings: - Among the 316 SCC cases, 21 cases (6.6%) had known treatable targets detected, including EGFR mutations, KRAS G12C mutations, ALK fusions, EGFR fusions and METex14 skipping events. - Most of the patients carrying these targets were over 50 years old and had a smoking history of more than 15 pack - years, which did not meet the molecular detection criteria recommended in current guidelines. - These targets were found in tumors at different stages, indicating that molecular detection should not be affected by tumor staging. ### Conclusions: - This study provides empirical support, indicating that it is necessary to perform extensive molecular detection on all newly diagnosed NSCLC cases, regardless of their histological type, age or smoking status. - Based on these data, the authors recommend the adoption of a more extensive molecular detection strategy in clinical practice to ensure that all patients who may benefit can receive appropriate targeted therapy.

Expanding Broad Molecular Reflex Testing in Non-Small Cell Lung Cancer to Squamous Histology

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

Brief Report: Impact of reflex testing on tissue-based molecular genotyping in patients with advanced non-squamous non-small cell lung cancer

Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium.

The Impact of Next-Generation Sequencing Workflows on Outcomes in Advanced Lung Cancer: A Retrospective Analysis at One Academic Health System

Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing

Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer-A Single-Center Experience

Preselection based on clinical characteristics in German non-small-cell lung cancer patients screened for EML4-ALK translocation

Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small-Cell Lung Cancer

Development, testing and validation of a targeted NGS-panel for the detection of actionable mutations in lung cancer (NSCLC) using anchored multiplex PCR technology in a multicentric setting

The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing

Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience

Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine

Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice

A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies

Precision medicine in non-small cell lung cancer: Current applications and future directions

Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective

Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC